Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2024-03-25 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2023 年年度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document includes comprehensive financial figures, management commentary, risk disclosures, and detailed business descriptions typical of a full annual report. The length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-03-25 Chinese
2023年度独立董事述职报告（王学恭）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the Year 2023" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's background, duties performed during the year, attendance at board and committee meetings, opinions on various company matters including financial reports, internal controls, audit firm reappointment, management appointments, remuneration, and employee stock plans. The document is a detailed narrative report on the independent director's activities and oversight for the year 2023. It is not a full annual report or financial statement, nor is it a simple announcement or certification. It focuses on board/management information, specifically the independent director's role and activities, which fits the category of Board/Management Information (MANG). The document length (8869 characters) and content confirm it is a substantive report rather than a brief announcement or regulatory filing.
2024-03-25 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities firm (华英证券有限责任公司) acting as the sponsor for Shenzhen Salubris Pharmaceuticals Co., Ltd. It concerns the use of idle raised funds for cash management. The text includes specifics about the raised funds, investment projects, usage status, cash management details, risk analysis, internal controls, and opinions from the board, supervisory committee, and sponsor. It is a formal verification and opinion report on the company's compliance and use of raised funds, not a general financial report or earnings release. It is not an announcement of a report publication but a substantive report itself. The content aligns with an Audit Report / Information (AR) type, as it involves verification, compliance, and audit-like opinions on the use of funds, consistent with regulatory requirements and internal controls. The document is 4179 characters, which is substantive enough for a report rather than a brief announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-03-25 Chinese
2023年度独立董事述职报告（朱厚佳）
Management Reports Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, committee participation, supervision of financial reports, internal controls, and other governance-related activities during the year 2023. The content includes detailed descriptions of board meetings, audit committee activities, remuneration committee activities, and oversight of financial reporting and internal controls. It also discusses the director's evaluation of company governance and compliance with laws and regulations. This type of document is a management report focusing on the director's role and oversight of financial and governance matters, rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on management and governance activities. Therefore, the most appropriate classification is "Management Reports (MDA)." The document length (over 10,000 characters) and detailed content confirm it is a full report, not just an announcement or certification.
2024-03-25 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司2023年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 华英证券有限责任公司 regarding the 2023 annual verification of the storage and use of raised funds by 深圳信立泰药业股份有限公司. It includes extensive financial data on the amount of funds raised, their allocation, usage, balance, and management, as well as compliance with regulatory requirements. The document references regulatory guidelines related to fundraising and fund management, and includes audit opinions and detailed tables of fund usage. The content focuses on the management and use of capital raised through a non-public stock issuance, with no indication that it is an earnings release, annual report, or other types of filings. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (over 11,000 characters) and detailed financial data confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2024-03-25 Chinese
2023年度独立董事述职报告（刘来平）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, committee participation, and oversight activities during the year 2023. The content includes descriptions of governance activities, audit committee meetings, remuneration committee meetings, internal control evaluations, and other supervisory roles. It does not contain financial statements or quarterly/annual financial results but focuses on the independent director's role and governance oversight. This type of document is a management or board-related report focusing on governance and oversight rather than financial results or audit opinions. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements or reports related to board or senior management activities and changes. The document length and detail confirm it is a full report, not a brief announcement or certification, so it is not RNS or RPA. Hence, the classification is MANG with high confidence.
2024-03-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.